Terms ending in 2043
Every in-force patent on Cellectis's record whose computed term ends in 2043, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,618,048 | Dual Car-T Cells In force · High confidence | Cellectis S.A. | In force | High confidence | |
| US 12,534,744 | Methods to Genetically Modify Cells for Delivery of Therapeutic Proteins In force · High confidence | Cellectis S.A. | In force | High confidence | |
| US 12,753,220 | New mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy In force · High confidence | Cellectis | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.